1. Approximately 74% of schizophrenic patients discontinued their medications before 18 months, with the median being 6 months.
2. Olanzapine was found to have a significantly longer time to discontinuation than quetiapine and risperidone.
3. Olanzapine was associated with significantly more weight gain and increases in glycosylated hemoglobin, cholesterol, and triglycerides when compared to the other antipsychotics.
Original Date of Publication: September 2005
Study Rundown: The CATIE trial demonstrated that schizophrenic patients discontinued their antipsychotics at very high rates, thereby limiting the effectiveness of drug therapy. Olanzapine was found to be significantly more effective than other atypical antipsychotics (i.e., quetiapine, risperidone) in terms of time to discontinuation; however, olanzapine was also associated with significantly more weight gain and increases in glycosylated hemoglobin, cholesterol, and triglyceride levels. The study was funded by the National Institute of Mental Health. Pharmaceutical companies contributed drug supplies for the study and advice regarding dosing; they were not otherwise involved in the design of the study, or the analyses and interpretation of its results.
Click to read study in the NEJM (New England Journal of Medicine)
EvidencePulse™by 2 Minute Medicine®
How does CATIE apply to your patient?
Describe your patient and EvidencePulse weighs this trial against later evidence and current guidelines, with citations.
For a fuller review of the evidence, Deep research is a core feature of 2MM Max.
In-Depth [randomized, controlled trial]: Published in NEJM in 2005, the CATIE trial is a double-blind, randomized controlled study that sought to compare the relative effectiveness of atypical and typical antipsychotics. A total of 1,493 patients were recruited from 57 different centres across the United States, and were randomly assigned to receive olanzapine (7.5-30 mg daily), quetiapine (200-800 mg daily), risperidone (1.5-6 mg daily), ziprasidone (40-160 mg daily), or perphenazine (8-32 mg daily); all medications were administered as identical-appearing capsules. Patients were included in the study if they were between 18 and 65 years of age, if they were diagnosed with schizophrenia, and if they were able to take antipsychotics. The primary outcome was the discontinuation of treatment for any reason, as this represents a major problem in managing patients with schizophrenia. It was thought that this measure would represent the efficacy, safety, and tolerability of different treatment options. Secondary outcomes included reasons for discontinuation and scores on the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression (CGI) scale.
Approximately 74% of patients discontinued their assigned treatment before the 18-month mark, with the median time to discontinuation being about 6 months. The time to discontinuation was significantly longer in the olanzapine group, when compared to the quetiapine (HR 0.63), risperidone (HR 0.75), ziprasidone (HR 0.76), and perphenazine group (HR 0.78). After adjusting for multiple comparisons, however, significant differences only remained between olanzapine and quetiapine/risperidone. The study also demonstrated that PANSS and CGI scores significantly improved over time. Notably, olanzapine was significantly associated with greater weight gain, as well as greater increases in glycosylated hemoglobin, total cholesterol, and triglycerides when compared to the other study drugs.
Trials since this one
What later trials found on the same question.
- 2006
STAR*D trials I In The Classics
In patients who have not experienced remission of depression despite vigorous treatment with an SSRI, augmentation of treatment by adding buproprion or buspirone can achieve remission in approximately 30% of patients.
- 2006
STAR*D trials II In The Classics
In cases where citalopram fails or cannot be tolerated, approximately 1 in 4 patients will experience remission of their depression symptoms by switching to sustained-release buproprion, sertraline, or extended-release…
3 more since 2005
2MM+ See every trial since CATIE
2MM+ shows the full timeline of later trials on this question, with what each one found, and lets you save trials to reading lists for rounds, journal club and boards.
Citation: Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/nejmoa051688. Epub 2005 Sep 19. PMID: 16172203.
© 2013 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: PD
![Childhood ADHD associated with increased risk of suicide [Physician Comment]](https://www.2minutemedicine.com/wp-content/uploads/2013/03/PET-image1-e1377449984183-75x75.jpg)
